Esomeprazole Magnesium; Naproxen Patent Expiration

Esomeprazole Magnesium; Naproxen is Used for relieving symptoms of arthritis and reducing the risk of NSAID-associated gastric ulcers. It was first introduced by Horizon Medicines Llc in its drug Vimovo on Apr 30, 2010. 7 different companies have introduced drugs containing Esomeprazole Magnesium; Naproxen.


Esomeprazole Magnesium; Naproxen Patents

Given below is the list of patents protecting Esomeprazole Magnesium; Naproxen, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Vimovo US8945621 Method for treating a patient at risk for developing an NSAID-associated ulcer Oct 17, 2031 Horizon
Vimovo US9220698 Method for delivering a pharmaceutical composition to patient in need thereof Mar 10, 2031 Horizon
Vimovo US9393208 Method for delivering a pharmaceutical composition to patient in need thereof Sep 03, 2029 Horizon
Vimovo US6926907 Pharmaceutical compositions for the coordinated delivery of NSAIDs Feb 28, 2023

(Expired)

Horizon
Vimovo US8557285 Pharmaceutical compositions for the coordinated delivery of NSAIDs May 31, 2022

(Expired)

Horizon
Vimovo US8852636 Pharmaceutical compositions for the coordinated delivery of NSAIDs May 31, 2022

(Expired)

Horizon
Vimovo US8858996 Pharmaceutical compositions for the coordinated delivery of NSAIDS May 31, 2022

(Expired)

Horizon
Vimovo US9161920 Pharmaceutical compositions for the coordinated delivery of NSAIDs May 31, 2022

(Expired)

Horizon
Vimovo US9198888 Pharmaceutical compositions for the coordinated delivery of NSAIDs May 31, 2022

(Expired)

Horizon
Vimovo US9345695 Pharmaceutical compositions for the coordinated delivery of NSAIDs May 31, 2022

(Expired)

Horizon
Vimovo US9707181 Pharmaceutical compositions for the coordinated delivery of NSAIDs May 31, 2022

(Expired)

Horizon
Vimovo US6369085

(Pediatric)

Form of S-omeprazole Nov 25, 2018

(Expired)

Horizon
Vimovo US7411070

(Pediatric)

Form of S-omeprazole Nov 25, 2018

(Expired)

Horizon
Vimovo US7745466 Form of S-omeprazole Oct 13, 2018

(Expired)

Horizon
Vimovo US6369085 Form of S-omeprazole May 25, 2018

(Expired)

Horizon
Vimovo US7411070 Form of S-omeprazole May 25, 2018

(Expired)

Horizon
Vimovo US5900424

(Pediatric)

Omeprazole magnesium salt form Nov 04, 2016

(Expired)

Horizon
Vimovo US5900424 Omeprazole magnesium salt form May 04, 2016

(Expired)

Horizon
Vimovo US5714504

(Pediatric)

Compositions Aug 03, 2015

(Expired)

Horizon
Vimovo US5714504 Compositions Feb 03, 2015

(Expired)

Horizon
Vimovo US6875872

(Pediatric)

Compounds Nov 27, 2014

(Expired)

Horizon
Vimovo US6875872 Compounds May 27, 2014

(Expired)

Horizon



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Esomeprazole Magnesium; Naproxen's patents.

Given below is the list recent legal activities going on the following patents of Esomeprazole Magnesium; Naproxen.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 19 Jan, 2024 US9393208
Expire Patent 08 Jan, 2024 US9198888
Expire Patent 27 Nov, 2023 US9161920
Maintenance Fee Reminder Mailed 24 Jul, 2023 US9198888
Payment of Maintenance Fee, 8th Year, Large Entity 29 Jun, 2023 US9220698(Litigated)
Maintenance Fee Reminder Mailed 12 Jun, 2023 US9161920
Expire Patent 21 Nov, 2022 US8858996
Payment of Maintenance Fee, 8th Year, Large Entity 03 Aug, 2022 US8945621(Litigated)
Expire Patent 01 Aug, 2022 US7745466(Litigated)
Maintenance Fee Reminder Mailed 06 Jun, 2022 US8858996


Esomeprazole Magnesium; Naproxen's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List



Esomeprazole Magnesium; Naproxen Generics

Several generic applications have been filed for Esomeprazole Magnesium; Naproxen. The first generic version for Esomeprazole Magnesium; Naproxen was by Dr Reddys Laboratories Ltd and was approved on Sep 27, 2013. And the latest generic version is by Sciegen Pharmaceuticals Inc and was approved on Oct 11, 2023.

Given below is the list of companies who have filed for Esomeprazole Magnesium; Naproxen generic.


1. ACTAVIS LABS FL INC

Actavis Laboratories Fl Inc has filed for 2 different strengths of generic version for Esomeprazole Magnesium; Naproxen. All of these versions come by the name NAPROXEN AND ESOMEPRAZOLE MAGNESIUM. Given below are the details of the strengths of this generic introduced by Actavis Labs Fl Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 20MG BASE; 500MG tablet, delayed release Discontinued ORAL N/A Aug 24, 2022
EQ 20MG BASE; 375MG tablet, delayed release Discontinued ORAL N/A Aug 24, 2022


2. AJANTA PHARMA LTD

Ajanta Pharma Ltd has filed for 2 different strengths of generic version for Esomeprazole Magnesium; Naproxen. All of these versions come by the name NAPROXEN AND ESOMEPRAZOLE MAGNESIUM. Given below are the details of the strengths of this generic introduced by Ajanta Pharma Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 20MG BASE; 375MG tablet, delayed release Prescription ORAL AB Oct 6, 2022
EQ 20MG BASE; 500MG tablet, delayed release Prescription ORAL AB Oct 6, 2022


3. DR REDDYS

Dr Reddys Laboratories Ltd has filed for 2 different strengths of generic version for Esomeprazole Magnesium; Naproxen. All of these versions come by the name NAPROXEN AND ESOMEPRAZOLE MAGNESIUM. Given below are the details of the strengths of this generic introduced by Dr Reddys.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 20MG BASE; 375MG tablet, delayed release Prescription ORAL AB Feb 18, 2020
EQ 20MG BASE; 500MG

(reference standard)

tablet, delayed release Prescription ORAL AB Feb 18, 2020


4. DR REDDYS LABS LTD

Dr Reddys Laboratories Ltd has filed for 2 different strengths of generic version for Esomeprazole Magnesium; Naproxen. All of these versions come by the name NAPROXEN AND ESOMEPRAZOLE MAGNESIUM. Given below are the details of the strengths of this generic introduced by Dr Reddys Labs Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 20MG BASE; 375MG tablet, delayed release Prescription ORAL AB Sep 27, 2013
EQ 20MG BASE; 500MG tablet, delayed release Prescription ORAL AB Sep 27, 2013


5. MYLAN

Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Esomeprazole Magnesium; Naproxen. All of these versions come by the name NAPROXEN AND ESOMEPRAZOLE MAGNESIUM. Given below are the details of the strengths of this generic introduced by Mylan.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 20MG BASE; 375MG tablet, delayed release Discontinued ORAL N/A Jul 20, 2021
EQ 20MG BASE; 500MG tablet, delayed release Discontinued ORAL N/A Jul 20, 2021


6. SCIEGEN PHARMS INC

Sciegen Pharmaceuticals Inc has filed for 2 different strengths of generic version for Esomeprazole Magnesium; Naproxen. All of these versions come by the name NAPROXEN AND ESOMEPRAZOLE MAGNESIUM. Given below are the details of the strengths of this generic introduced by Sciegen Pharms Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 20MG BASE; 375MG tablet, delayed release Prescription ORAL AB Oct 11, 2023
EQ 20MG BASE; 500MG tablet, delayed release Prescription ORAL AB Oct 11, 2023